These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25518350)

  • 21. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of systemic therapies for localised prostate cancer.
    Eigl BJ; Gleave ME; Chi KN
    Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):506-13. PubMed ID: 23660300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
    Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
    J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current status of castration resistant prostate cancer basic research].
    Sakamoto S; Ichikawa T
    Nihon Rinsho; 2014 Dec; 72(12):2097-102. PubMed ID: 25518340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The concept and mechanisms of castration-resistant prostate cancer].
    Naito S; Shiota M
    Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug discovery in advanced prostate cancer: translating biology into therapy.
    Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS
    Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New era of the treatment of CRPC in Japan].
    Akaza H
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Recommendations for follow up in castration resistant prostate cancer.].
    Vázquez-Alonso F; Puche-Sanz I; Cózar-Olmo JM
    Arch Esp Urol; 2018 Sep; 71(8):735-742. PubMed ID: 30319133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential of oncolytic virus therapy for pancreatic cancer.
    Kasuya H; Takeda S; Nomoto S; Nakao A
    Cancer Gene Ther; 2005 Sep; 12(9):725-36. PubMed ID: 15818382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy.
    Wirth M; Heidenreich A; Gschwend JE; Gil T; Zastrow S; Laniado M; Gerloff J; Zühlsdorf M; Mordenti G; Uhl W; Lannert H
    Eur Urol; 2014 May; 65(5):897-904. PubMed ID: 23791392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model.
    Edamura K; Nasu Y; Takaishi M; Kobayashi T; Abarzua F; Sakaguchi M; Kashiwakura Y; Ebara S; Saika T; Watanabe M; Huh NH; Kumon H
    Cancer Gene Ther; 2007 Sep; 14(9):765-72. PubMed ID: 17599093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.